Litcius/Paper detail

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype

Vincenzo Carnovale, Paola Iacotucci, Vito Terlizzi, C. Colangelo, Pietro Medio, Lorenza Ferrillo, Fabiola De Gregorio, Michela Francalanci, Giovanni Taccetti, S. Buonaurio, M. d’Ippolito, Giovanni Marsicovetere, Michele D’Andria, Nicola Ferrara, Donatello Salvatore

2021Respiratory Medicine48 citationsDOI

Topics & Concepts

IvacaftorMedicineCystic fibrosisCystic fibrosis transmembrane conductance regulatorInternal medicineCohortBody mass indexLung transplantationGastroenterologyConfidence intervalCombination therapyLungSurgeryCystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchBiological Research and Disease Studies
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype | Litcius